NS3, NS4A: Hepatitis C virus serine protease, NS3/NS4A
Complex in Hepatitis C virus that 17 drugs act on.
- Drugs that act on it: 17
- Approved: 8
- In phases 1 to 3: 9
- Sponsors: 11
Who is on it, and how far along
Every drug ChEMBL records acting on NS3, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 17
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- Gilead Sciences318%
- Merck & Co. (MSD)318%
- AbbVie212%
- Ascletis Pharmaceuticals Co., Ltd.16%
- AstraZeneca Pharmaceuticals16%
- Boehringer Ingelheim Pharmaceuticals16%
- Bristol-Myers Squibb16%
- Johnson & Johnson16%
- R-Pharm16%
- TaiGen Biotechnology Co., Ltd.16%
| Glecaprevir | Approved | AbbVie | Small molecule | Inhibitor | 4 |
| Voxilaprevir | Approved | Gilead Sciences | Small molecule | Inhibitor | 4 |
| Paritaprevir | Approved | AbbVie | Small molecule | Inhibitor | 1 |
| Asunaprevir | Approved | Bristol-Myers Squibb | Small molecule | Inhibitor | 0 |
| Boceprevir | Approved | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| Grazoprevir anhydrous | Approved | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| SimeprevirBoxed warning | Approved | Johnson & Johnson | Small molecule | Inhibitor | 0 |
| TelaprevirBoxed warning | Approved | Vertex Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Danoprevir | Phase 3 | Ascletis Pharmaceuticals Co., Ltd. | Small molecule | Inhibitor | 0 |
| Faldaprevir | Phase 3 | Boehringer Ingelheim Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Furaprevir | Phase 3 | TaiGen Biotechnology Co., Ltd. | Small molecule | Inhibitor | 0 |
| Narlaprevir | Phase 3 | R-Pharm | Small molecule | Inhibitor | 0 |
| Vaniprevir | Phase 3 | Merck & Co. (MSD) | Small molecule | Inhibitor | 0 |
| Ciluprevir | Phase 2 | — | Small molecule | Inhibitor | 0 |
| GS-9256 | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
| Sovaprevir | Phase 2 | AstraZeneca Pharmaceuticals | Small molecule | Inhibitor | 0 |
| Vedroprevir | Phase 2 | Gilead Sciences | Small molecule | Inhibitor | 0 |
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2095231, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets